- Previous Close
53.89 - Open
52.84 - Bid 51.99 x 400
- Ask 52.13 x 100
- Day's Range
51.58 - 53.92 - 52 Week Range
16.72 - 53.92 - Volume
461,263 - Avg. Volume
560,437 - Market Cap (intraday)
3.175B - Beta (5Y Monthly) 2.04
- PE Ratio (TTM)
-- - EPS (TTM)
-4.63 - Earnings Date Jul 30, 2024 - Aug 5, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
57.22
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
rhythmtx.comRecent News: RYTM
View MorePerformance Overview: RYTM
Trailing total returns as of 7/17/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RYTM
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RYTM
View MoreValuation Measures
Market Cap
3.29B
Enterprise Value
3.09B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
34.31
Price/Book (mrq)
53.36
Enterprise Value/Revenue
33.57
Enterprise Value/EBITDA
-12.65
Financial Highlights
Profitability and Income Statement
Profit Margin
-297.93%
Return on Assets (ttm)
-56.20%
Return on Equity (ttm)
-194.69%
Revenue (ttm)
91.93M
Net Income Avi to Common (ttm)
-273.87M
Diluted EPS (ttm)
-4.63
Balance Sheet and Cash Flow
Total Cash (mrq)
201.2M
Total Debt/Equity (mrq)
176.10%
Levered Free Cash Flow (ttm)
-188.31M
Research Analysis: RYTM
View MoreCompany Insights: RYTM
RYTM does not have Company Insights